Therefore, the expression levels of FLT3 and Bcl-2 of THP-1 cells were found to be clinically relevant, and we speculated that the anti-tumor effect of ASP1235 could be potentiated by the combination treatment with venetoclax plus azacitidine regimen, a novel standard-of-care treatment for elderly patients with AML. This evidence concerns the gene FLT3 and neoplasm.